Replimune Group Inc
Replimune Group Inc logo
REPL

Replimune Group Inc (REPL)

$20.474.07%

Market is closed
– opens on 8 PM, 01 Dec 2022
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$19.52
Day's Range
$20.705
$13.05
52-Week Range
$30.89
1 month return7.14%
3 month return2.88%
1 year return30.96%
5 year return29.75%

Company Information

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications.
OrganizationReplimune Group Inc
Employees206
CEOMr. Philip Astley-Sparke FSA
IndustryHealth Technology

Analyst Recommendation

based on 10 analysts ratings

Buy
100%
Buy
0%
Hold
0%
Sell

Based on 10 Wall street analysts offering stock ratings for Replimune Group Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 118.86%

Current

$20.47

Target

$44.8

Recommendation Trend

Based on 10 analyst

Current1M Ago3M Ago
Buy
10
15
15
Hold
0
1
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Highlights

Market Capitalization
964.9M
Book Value
$7.72
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.26
Wall Street Target Price
44.8

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)
2.59
Enterprise Value
654.6M
Enterprise Value/Revenue
0.0
Enterprise Value/Ebitda
-4.6

Technicals

Beta
1.86
50 Day MA
18.06
200 Day MA
17.67

Institutional Holdings

T. Rowe Price Associates, Inc.

11.83%

Omega Fund Management LLC

8.62%

Redmile Group, LLC

7.33%

Baker Bros Advisors LP

7.22%

Vanguard Group Inc

3.72%

State Street Corporation

2.92%

Discover more

Frequently Asked Questions

What is Replimune Group Inc share price today?

Can Indians buy Replimune Group Inc shares?

How can I buy Replimune Group Inc shares from India?

Can Fractional shares of Replimune Group Inc be purchased?

What are the documents required to start investing in Replimune Group Inc stocks?

What are today’s High and Low prices of Replimune Group Inc?

What are today’s traded volumes of Replimune Group Inc?

What is today’s market capitalisation of Replimune Group Inc?

What is the 52 Week High and Low Range of Replimune Group Inc?

How much percentage Replimune Group Inc is down from its 52 Week High?

How much percentage Replimune Group Inc is up from its 52 Week low?

What are the historical returns of Replimune Group Inc?

Who is the Chief Executive Officer (CEO) of Replimune Group Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*